• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Stock

Trump announces new drug-pricing deals with 9 pharma companies

by September 1, 2026
written by September 1, 2026

President Donald Trump announced a new round of drug-pricing agreements with international pharmaceutical companies and some smaller biotechs on Monday, part of a push to make healthcare more affordable for Americans.

Deals were signed with nine companies, including Astellas, BeOne Medicines, CSL, BridgeBIO, Sun Pharmaceutical, Teva and UCB.

These companies have offered drugs to state Medicaid programs at most-favored-nation prices, Trump said in an Oval Office event with executives of the companies, describing this as “a tremendous discount, which should bring down the cost of your medical care by tremendous amounts.”

U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.

The deals will build on agreements the administration struck with 17 of the world’s largest drugmakers, including Pfizer, Eli Lilly and Amgen, starting last year. The drugmakers agreed to offer lower prices comparable to what is paid in other developed countries, referred to as “most-favored-nation” pricing.

Those companies agreed to cut some prices for federal health programs and sell some medicines directly to patients through a Trump-branded website, in return for tariff relief.

Smaller and midsized drugmakers had been slow to sign on to drug-pricing deals, Reuters has reported.

A Reuters report in June found that only Japan’s Astellas had confirmed applying for the Medicaid pricing program by that point, with executives at companies such as Ionis Pharmaceuticals saying they saw little financial benefit in joining.

It is not yet clear how much the deals will save the government or patients. Medicaid already gets steep discounts from drugmakers under existing law, and most people covered by the program pay little out of pocket for prescriptions.

The White House has held several high-profile events with pharmaceutical executives this year to promote its efforts on healthcare costs, part of a broader push to highlight affordability before this year’s midterm elections that will decide control of Congress.

The administration has said its broader drug-pricing push, including the earlier deals with large pharmaceutical companies, could save $64.3 billion in federal and state spending over the next decade, but that number is speculative.

This post appeared first on https://www.nbcnews.com

0 comment
0
FacebookTwitterPinterestEmail

previous post
Nvidia stock analysis: top reasons why the shares may go parabolic soon
next post
Smucker’s lawsuit against Trader Joe’s over frozen PB&J can proceed, judge rules

related articles

Dutch central bank shifts billions in gold from...

September 3, 2026

U.S. oil giant Chevron confirms it will expand...

September 3, 2026

Internal probe finds Dianna Russini’s ties to Patriots...

September 3, 2026

Bill Simmons under review by Massachusetts authorities after...

September 3, 2026

The sardine shortage is real — and it’s...

September 2, 2026

No pint-sized matter: Thieves steal $70,000 in Pabst...

September 1, 2026

Tony Romo admits to ‘over-reliance on alcohol’ after...

September 1, 2026

Shares in fast fashion retailer Shein slide in...

September 1, 2026

Trump calls for federal tax incentives to benefit...

September 1, 2026

Days after Trump announces Venezuela oil deal, White...

September 1, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • US stocks poised for continued gains through year-end: find out more

    June 30, 2026
  • Fiserv stock rises 6% as top US banks reportedly consider buying its card network

    July 7, 2026
  • Minnesota ‘outstanding refugee’ honoree accused in fraud scheme tied to sex trafficking: ‘Can’t make this up’

    August 18, 2026
  • DJT stock analysis: What comes next for Trump Media after the midterm elections?

    November 4, 2026
  • Why Robinhood stock’s fresh bullish upgrade could be a warning sign

    September 7, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Dow rises 260 points as weak jobs data lifts US stocks

    October 2, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,690)
  • Stock (90)

Latest Posts

  • Goldman Sachs stock forms a risky pattern ahead of earnings

    July 13, 2026
  • Why are Micron, SK Hynix, and SanDisk stocks climbing on Friday?

    October 23, 2026
  • Socialist insurgents eye Midwest gains as Dem civil war threatens must-hold Senate seat

    August 4, 2026

Recent Posts

  • European shares hold steady as tech stocks gain amid Middle East ceasefire hopes

    June 29, 2026
  • El-Sayed tries to make peace with Jewish Democrats but draws line at dumping Hasan Piker

    August 31, 2026
  • Samsung and SK Hynix stocks fall again as Nvidia earnings boost fades

    November 19, 2026

Editor’s Pick

  • Key swing state voters to settle dueling Senate primary fights in crucial open-seat race

    September 8, 2026
  • As the AI model race heats up, who will come out on top?

    October 31, 2026
  • 4 GOP senators rebel against Trump on Iran war, vote with Dems to rein in authority

    September 24, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock